Skip to main content
Displaying 61 - 71 of 71
Display:
12
24
48
Viral Hepatitis
5
Gilead Sciences: The Next Chapter in Viral Hepatitis - ILC 2021
View
Viral Hepatitis
5
Gilead Sciences: The Next Chapter in Viral Hepatitis - ILC 2021
View
Viral Hepatitis
4
AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020
View
Viral Hepatitis
4
AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020
View
Viral Hepatitis
4
AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020
View
Viral Hepatitis
4
AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Pagination
First page
« First
Previous page
‹ previous
Page
1
Page
2
Page
3
Page
4
Page
5
Current page
6
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy